Open an account

Adhera Therapeutics

ATRX · OTC

$0.0001−$0.0001 (−50.00%)TodayMarket closed ·
No price history for this range.

About ATRX

Adhera Therapeutics, Inc. is an emerging specialty biotech company, which is in the process of evaluating its focus including a return to drug discovery and development. The company is headquartered in Wake Forest, North Carolina. The firm is focused on the drug development and commercialization of small molecule drugs to treat Parkinson's disease (PD) and Type 1 diabetes. The firm has two drug candidates: MLR-1019 and MLR-1023. The company is engaged in developing MLR-1023 (tolimidone) as a new drug for Type I Diabetes with a focus on C-peptide positive patients. Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions. MLR-1023, a lyn kinase activator, has demonstrated clinical safety and tolerability in over 700 patients in Phase IIa and Phase IIb Type 2 diabetes studies. MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease.

Employees
0
Headquarters
Wake Forest, North Carolina
Listed
Apr 15, 1994
Sector
Health Care
Industry
Biotechnology
Website
adherathera.com

ATRX key statistics

Market cap
722
Price-earnings ratio
0.00
Dividend yield
—
Average volume
20.00K
Volume
1
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.0001
52 Week low
$0.00

Adhera Therapeutics (ATRX) at a glance

Adhera Therapeutics (ATRX) last traded at $0.0001, with a market cap of 722 and a price-to-earnings ratio of 0.00.

Volume so far is 1 shares, below the average of 20.00K shares a day.

Over the past year Adhera Therapeutics has ranged from $0.00 to $0.0001, and now sits 100% of the way up that range.

Adhera Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY11 it reported -$100.00 per share against an estimate of -$142.80.

ATRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 36.9% on average.

  1. Q4 FY09: reported -$160.00 per share against an estimate of -$1,428.00
  2. Q1 FY10: reported -$1,600.00 per share against an estimate of -$1,142.40
  3. Q2 FY10: reported -$680.00 per share against an estimate of -$469.20
  4. Q3 FY10: reported -$700.00 per share against an estimate of -$870.40
  5. Q4 FY10: reported -$460.00 per share against an estimate of -$469.20
  6. Q1 FY11: reported -$240.00 per share against an estimate of -$224.40
  7. Q2 FY11: reported -$160.00 per share against an estimate of -$285.60
  8. Q3 FY11: reported -$100.00 per share against an estimate of -$142.80

Similar companies

Companies in the same industry as Adhera Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.